What is NDC 33342-447?

33342-447 is the product NDC for Pyrazinamide, Pyrazinamide 500 mg/1 tablet, listed with the FDA by Macleods Pharmaceuticals Limited. It has 7 package NDCs, shown above in 10- and 11-digit form.

Macleods Pharmaceuticals Limited, NDC labeler code 33342. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Pyrazinamide?

4 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Pyrazinamide NDC 33342-447 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)33342-447Labeler and product segments. Claims need a package NDC.

Product NDC at billing width33342-0447Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
33342-447-03	3334204470333342044703	10 TABLET in 1 BOTTLE (33342-447-03)Marketed from Jul 27, 2020
33342-447-07	3334204470733342044707	30 TABLET in 1 BOTTLE (33342-447-07)Marketed from Jul 27, 2020
33342-447-09	3334204470933342044709	60 TABLET in 1 BOTTLE (33342-447-09)Marketed from Jul 27, 2020
33342-447-10	3334204471033342044710	90 TABLET in 1 BOTTLE (33342-447-10)Marketed from Jul 27, 2020
33342-447-11	3334204471133342044711	100 TABLET in 1 BOTTLE (33342-447-11)Marketed from Jul 27, 2020
33342-447-12	3334204471233342044712	10 TABLET in 1 BLISTER PACK (33342-447-12)Marketed from Jul 27, 2020
33342-447-15	3334204471533342044715	500 TABLET in 1 BOTTLE (33342-447-15)Marketed from Jul 27, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pyrazinamide
Generic name (nonproprietary): pyrazinamide
Active ingredients: Pyrazinamide — 500 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Macleods Pharmaceuticals LimitedNDC labeler code 33342
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212541
Marketing start: Jul 27, 2020
Listing expires: Dec 31, 2026
Identifiers: Product ID 33342-447_3695f057-de86-4c9a-9d43-ff0a6acdffe7SPL ID 3695f057-de86-4c9a-9d43-ff0a6acdffe7SPL set ID a8b7ba02-8509-475b-8a3b-39d205af3f1eRxCUI 198181UNII 2KNI5N06TIUPC 0333342447104, 0333342447098, 0333342447111, 0333342447159
Pharmacologic class: Antimycobacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N433342044703 followed by a unit qualifier and the quantity

Package 33342-0447-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 6, 2022.

Indications (excerpt from the label)

INDICATIONS & USAGE: Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug- susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of curren…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 33342-447

What is NDC 33342-447?: 33342-447 is the product NDC for Pyrazinamide, Pyrazinamide 500 mg/1 tablet, listed with the FDA by Macleods Pharmaceuticals Limited. It has 7 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Pyrazinamide.
What is the active ingredient?: Pyrazinamide.
Who is the labeler?: Macleods Pharmaceuticals Limited, NDC labeler code 33342. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Pyrazinamide?: 4 other product NDCs are listed under this name. See all Pyrazinamide NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Pyrazinamide NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
pyrazinamide	Pyrazinamide 500 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc	0054-0812	00054-0812-2100054-0812-2200054-0812-25+1 more
Pyrazinamide	Pyrazinamide 500 mg/1	TabletOral	American Health Packaging	60687-789	60687-0789-01
Pyrazinamidepyrazinamide tablet	Pyrazinamide 500 mg/1	TabletOral	MARLEX PHARMACEUTICALS, INC	10135-735	10135-0735-0110135-0735-6010135-0735-90
Pyrazinamide	Pyrazinamide 500 mg/1	TabletOral	ANI Pharmaceuticals, Inc.	70954-484	70954-0484-1070954-0484-2070954-0484-30